Pediatric CAP Duration Update | UConn P4 💬 ⚕️🏥 By Nicole P
"How Long Should We Treat Pediatric Outpatient CAP? Rethinking Antibiotic Duration" Posted March 6, 2026
pharmacy.uconn.edu/pediatric-id...
Note these components are all different than what was included in the 2025-2026 flu vaccines.
Cell and Recombinant 2026-2027 influenza vaccine components:
- A/Missouri/11/2025(H1N1)pdm09-like virus;
- A/Darwin/1454/2025(H3N2)-like virus;
- B/Pennsylvania/14/2025 (B/Victoria lineage)
Egg Based 2026-2027 influenza vaccine components:
- A/Missouri/11/2025(H1N1)pdm09-like virus;
- A/Darwin/1454/2025(H3N2)-like virus;
- B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus
🧵FDA advisory committee has voted to recommend the following components for the 2026-2027 influenza vaccines
FDA having their influenza vaccine advisory committee meeting today to vote on products for the 2026-2027 season. This will also include information on current vaccine effectiveness and likely circulating strains. Meeting live at www.youtube.com/live/WKw0WEi...
Applying the Data
1/2026: Multi-modeling analysis of HPV dosing
Models predicted 90% reduction by year 2100 in HPV infection and cervical cancer incidence with 1-dose regimen.
1-dose of HPV may become standard in the US soon
pmc.ncbi.nlm.nih.gov/articles/PMC...
#PedsIDsky #RXsky
New Literature
12/2025: Clinical Trial HPV 1 vs 2 dose series
Population: Girls 12-16 y/o in Puerto Rico (n= 20,330)
Results: Non-inferiority of 1 vs 2 doses; Difference of 0.21 infections/100 persons (95% CI, -0.09 to 0.51; P<0.001) pubmed.ncbi.nlm.nih.gov/41337735/
#PedsIDsky #RXsky
Guideline Recommendations for Healthy Pediatrics
AAP: 9-14 y/o- 2 doses, (if beginning series at >15 y/o- 3 doses recommended)
CDC: 1 dose at 11-12 y/o
WHO: 1-2 doses at 9-14 y/o
#PedsIDsky #RXsky
HPV Vaccination
88% decrease in HPV infections among 14-19 y/o females since vaccine introduction in 2006 Available product: (Gardasil 9) nonavalent vaccine Immunization can protect against HPV infection and related cancers
#PedsIDsky #RXsky
🔁 🧵 Pharmacy Update | UConn P4 HPV Immunization Review 💬 ⚕️💉 By Megan.
Another recent publication w/the PPA Immunization Committee, we highlight the importance of the hepatitis B vaccine at birth. 👶💉
🔗 jppt.kglmeridian.com/view/journal...
#PedsIDsky #Rxsky
Here is is our PPA Immunization Committee publication to support pharmacists in immunization practice. 💉📚
This article provides evidence-informed strategies and practical resources to strengthen vaccine conversations with families.
🔗 jppt.kglmeridian.com/view/journal...
#PedsIDsky #Rxsky
Bacterial arthritis in pediatrics, key takeaways for pharmacy practice by Kenna Riley. www.instagram.com/p/DTvxxhOiUq... Full article available pharmacy.uconn.edu/pediatric-id... #Rxsky
A JAMA article titled "Influenza A(H3N2) Subclade K Virus Threat and Response" shows diagrams of the influenza virus, highlighting antigenic sites and amino acid changes. Labels indicate receptor-binding sites and glycosylation sites.
💬 Perspective: The rise of H3N2 subclade K may increase severe #influenza outcomes this season; available vaccines and antivirals remain important tools for prevention and treatment.
ja.ma/3MVJMt1
4️⃣ 🚨 Treat early! Antivirals recommended for:
✔️ High-risk patients (incl children <2 / <5 yrs and adults ≥65 yrs)
✔️ Chronic medical conditions
✔️ Progressive disease
✔️ All hospitalized patients
🔗 Who is high risk? www.cdc.gov/flu/highrisk...
#PedsIDsky #RXsky
3️⃣ 🦠 Influenza A (H3N2) predominates
➡️ ~90% of subtyped isolates ( ~90% of these = K subtype)
Luckily! 💊 All tested strains remain susceptible to neuraminidase inhibitors (e.g., oseltamivir) and baloxavir
#PedsIDsky #RXsky
2️⃣ 🌎 High / very high flu activity in ~1/3 of states
📍 Southern New England, NY, NJ, LA, CO, ID, MI, SC
👶📊 Highest outpatient/ED flu visits in younger age groups
#PedsIDsky #RXsky
🧵 CDC FluView Update (12/19)
📈 Flu activity is rising: 2nd week above baseline
🤒 ILI ~4% nationwide
🧪 Flu test positivity ↑ ~15% this week
🔗 CDC FluView Week 50: www.cdc.gov/fluview/surv...
#PedsIDsky #RXsky
📢 In a time where vaccine hesitancy is rising, the Pediatric Pharmacy Association’s Immunization Committee has published guidance on how to build immunization confidence through communication, education, and trusted resources.
Read more here: jppt.kglmeridian.com/view/journal...
#Rxsky
Grateful for the clear messages coming from @ameracadpeds.bsky.social @idsainfo.bsky.social @apha.org
The decision by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention to downgrade its recommendations to protect infants from hepatitis B is a dangerous move that will harm children.
Click here to read AAP's full statement: bit.ly/3Y9ZQJT
#ACIP votes to change the #hepatitisB #vaccine birth dose recommendation, ending the universal birth dose policies that have almost eliminated neonatal hepatitis B infection, cut pediatric infections by more than 95%, and prevented more than 6 million infections / a million hospitalizations.
It's hard to predict what the new #ACIP will do, but it looks like it will recommend that the universal birth dose for #hepatitisB be jettisoned. Experts warn even a delay of 2 months before the first dose will lead to chronically infected kids & deaths. www.statnews.com/2025/12/04/c...
ACIP meeting is about to start. The updated proposed HepB vote language has been posted. www.cdc.gov/acip/meeting...
This language is confusing and if passed will result in more infants exposed.
The vote was slightly different than what was published and was delayed until tomorrow so members were able to fully review the updated options and language before voting.
False claims often link childhood vaccines, including the hepatitis B (HBV) vaccine, to sudden infant death syndrome (SIDS). In reality, many studies have looked at this issue and found no connection between vaccines and SIDS. While most studies examined the full set of childhood vaccines rather than HBV alone, at least one study focused just on HBV and still found no link. During this meeting, the ACIP committee is likely to cite this study which at first glance seemed to have found a higher rate of SIDS deaths in the vaccinated group, but the total overall number of unexpected infant deaths due to any cause was not statistically significantly different between HBV vaccinated and unvaccinated groups (p=0.6). In the initial analysis, they looked at deaths of infants who had received the Hep B vaccine. In this group, there were 8 SIDS deaths. By contrast, the group of infant deaths in the matched unvaccinated group that was used for comparison had no SIDS deaths, but did have a lot of other causes of death. This initial imbalance likely reflects confounding: the matched unvaccinated infants were more medically fragile or unhealthy overall, and at higher risk for mortality from other causes, making them an inappropriate comparison group. To address this, the authors calculated SIDS rates using the full population—240,717 vaccinated infants (including the 8 SIDS deaths mentioned above, 3.3 per 100,000 births), and 120,979 unvaccinated newborns (including four additional SIDS cases not captured in the matched subset, also 3.3 per 100,000 births). The resulting identical rates (P = 0.99) show no statistical difference in SIDS risk between HBV vaccinated and unvaccinated newborns.
A study cited in today's ACIP meeting about Hep B and SIDS was misrepresented. The study's authors themselves have refuted an association.
If anyone is looking for a bit more in depth info on the HBV vaccine, you may find this helpful www.cidrap.umn.edu/vaccine-inte...
A "JAMA" article, published online December 3, 2025, titled "Universal Hepatitis B Vaccination at Birth—Risks of Revising the Recommendation" by Michael S. Abers et al., discusses ACIP's review and a possible vote to eliminate the birth dose recommendation.
💬Viewpoint: Eliminating universal hepatitis B birth dose vaccination risks an estimated 8% increase in annual perinatal #HepatitisB infections in the US, increasing preventable chronic disease burden. ja.ma/3Me0zHh
